Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

169 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

D-Cycloserine Enhancement of Exposure in Social Phobia

NCT00633984

Social Anxiety Disorder

COMPLETED PHASE4

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792

Social Anxiety Disorder

COMPLETED EARLY_PHASE1

Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia

NCT00128401

Phobic Disorders Anxiety Social Phobia

COMPLETED PHASE2

D-cycloserine Augmented CBT for Panic Disorder

NCT01680107

Panic Disorder

TERMINATED PHASE3

D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia

NCT01102803

Phobic Disorders

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Social anxiety disorder (SAD) is among the most common psychiatric conditions and is associated with significant distress and dysfunction in social situations. Although treatment with cognitive-behavior therapy (CBT) is known to help remedy SAD, many patients do not respond to this treatment and most do not reach full recovery. In CBT, patients undergo repeated and prolonged exposure practices to feared social situations to learn better ways to deal with anxiety in these settings. Exposure therapy is based on animal models of extinction of conditioned fears, and recent animal research has identified some of the core pathways and neurotransmitters involved in fear extinction. D-cycloserine (DCS) is a drug that appears to facilitate learning and the process of extinction of conditioned fear in both animals and humans. This study will assess the effectiveness of DCS combined with CBT in treating people with SAD.

Participants in this double-blind study will be randomly assigned to an active or control group. All participants will attend 18 study visits at the Center for Anxiety and Related Disorders over a 9-month period. There will be 12 CBT sessions of 90 minutes each and 6 assessment visits. The CBT sessions will help participants to become more comfortable with social situations. During 5 of the CBT sessions, participants will receive a pill containing either DCS or sugar (placebo). Assessment visits will include interviews, self-report questionnaires, and laboratory tests. These visits will occur at Weeks 1, 7, and 12 during treatment and at Months 3, 6, and 9 post-treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CBT plus d-cycloserine

Participants will receive cognitive behavioral therapy plus D-cycloserine

Group Type EXPERIMENTAL

D-cycloserine

Intervention Type DRUG

50 mg

Cognitive behavioral therapy (CBT)

Intervention Type BEHAVIORAL

CBT sessions aim to help participants become more comfortable with social situations.

CBT plus placebo

Participants will receive cognitive behavioral therapy plus pill placebo

Group Type PLACEBO_COMPARATOR

Cognitive behavioral therapy (CBT)

Intervention Type BEHAVIORAL

CBT sessions aim to help participants become more comfortable with social situations.

Placebo

Intervention Type DRUG

Same dosage as active pill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-cycloserine

50 mg

Intervention Type DRUG

Cognitive behavioral therapy (CBT)

CBT sessions aim to help participants become more comfortable with social situations.

Intervention Type BEHAVIORAL

Placebo

Same dosage as active pill

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Seromycin Sugar pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets DSM-IV criteria for generalized social anxiety disorder (GSAD)
* Total score of greater than or equal to 60 on the LSAS
* Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities

Exclusion Criteria

* Lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders, or obsessive-compulsive disorder
* Eating disorder within the 6 months prior to study entry
* History of organic brain syndrome, mental retardation, or other cognitive dysfunction
* Substance or alcohol abuse or dependence (other than nicotine) within the 6 months prior to study entry or inability to refrain from alcohol use during the acute period of study participation
* Post-traumatic stress disorder within 6 months prior to study entry; entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder
* Suicidal thoughts
* Taking concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) within 2 weeks of study entry
* Significant personality dysfunction
* Serious medical illness or instability for which hospitalization may be likely within the next year

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No